Docoh
Loading...

Invus Financial Advisors

Filed: 16 Nov 20, 4:00pm

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number:3235-0006
Expires:Oct 31, 2018
Estimated average burden
hours per response:23.8

COLUMN 1COLUMN 2COLUMN 3COLUMN 4COLUMN 5COLUMN 6COLUMN 7COLUMN 8
VALUESHRS ORSH/PUT/INVESTMENTOTHERVOTING AUTHORITY
NAME OF ISSUERTITLE OF CLASSCUSIP(x$1000)PRN AMTPRNCALLDISCRETIONMANAGERSOLESHAREDNONE
Arcus Biosciences IncCOM03969F10931,5731,842,077SH SOLE 1,842,07700
Novocure LtdORD SHSG6674U10839,057350,884SH SOLE 350,88400
Oric Pharmaceuticals IncCOM68622P10925,1991,007,576SH SOLE 1,007,57600
Oyster Point Pharma IncCOM69242L10658,4452,768,586SH SOLE 2,768,58600
Unity Biotechnology IncCOM91381U1013,7891,094,998SH SOLE 1,094,99800
Yext IncCOM98585N10649,8043,280,885SH SOLE 3,280,88500